Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524B in Primary Hypercholesterolemia or Mixed Hyperlipidemia
NCT00269217Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2006
- Primary completion
- Jan 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of Niacin + laropiprant + simvastatin in hypercholesterolemia and mixed hyperlipidemia (3 arms), sponsored by Merck & Co. Primary endpoint: Low-Density Lipoprotein Cholesterol reduction at 12 weeks. Started Jan 2006; status: completed.
02
Drugs
Niacin + laropiprant + simvastatin
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT00269217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269217.